Associate Director, Program Management — Asset Diligence & Integration

A builder who designs fit-for-purpose processes and scales operational excellence.

Thrive in high-growth, high-ambiguity environments and drive alignment and momentum.

Curious about and eager to leverage AI and automation to improve PM efficiency and derive insights.

6+ years in program or project management within the life science, biotech, or pharmaceutical industry.

Proven ability to integrate cross-functional inputs into actionable, business-driven plans.

Familiarity with term sheets, diligence workplans, asset integration, and regulatory/quality transitions a plus.

Salary ranges are informed by a number of factors including geographic location. The range provided includes base salary only. In addition to base salary, we offer equity, comprehensive benefits, generous perks, hybrid flexibility, and more. If this range doesn't match your expectations, please still apply because we may have something else for you.

You will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.

#LI-hybrid

Associate Director, Program Management - Asset Diligence & Integration

to partner with our Business Development (BD) and cross-functional teams across the end-to-end asset diligence lifecycle—from initial screen through confirmatory diligence and integration.

This role will lead late-stage diligence efforts, support asset onboarding post-acquisition, and help build scalable program management infrastructure that enhances execution, visibility, and governance.

Depending on portfolio needs, you may also flex into post-acquisition program management, driving near-term development milestones until steady-state ownership is established.

Lead and manage the full diligence process from initial evaluation to pre-close.

Coordinate cross-functional workstreams (Clinical, CMC, Regulatory, Nonclinical, QA, Commercial, Finance, Legal/IP).

Formation Bio is a tech and AI driven pharma company differentiated by radically more efficient drug development.

Advancements in AI and drug discovery are creating more candidate drugs than the industry can progress because of the high cost and time of clinical trials. Recognizing that this development bottleneck may ultimately limit the number of new medicines that can reach patients, Formation Bio, founded in 2016 as TrialSpark Inc., has built technology platforms, processes, and capabilities to accelerate all aspects of drug development and clinical trials. Formation Bio partners, acquires, or in-licenses drugs from pharma companies, research organizations, and biotechs to develop programs past clinical proof of concept and beyond, ultimately helping to bring new medicines to patients. The company is backed by investors across pharma and tech, including a16z, Sequoia, Sanofi, Thrive Capital, Sam Altman, John Doerr, Spark Capital, SV Angel Growth, and others.

You can read more at the following links:

Our Vision for AI in Pharma

Our Current Drug Portfolio

Our Technology & Platform